Brief: Nanexa And Novo Enter Global License, Collaboration Deal
BRIEF-Nanexa And Novo Enter Global License, Collaboration Deal Sept 25 (Reuters) - Nanexa AB NANEXA.ST:
SAID ON THURSDAY CO AND NOVO NORDISK ENTER GLOBAL LICENSE, COLLABORATION DEAL WORTH UP TO EUR 1.165 BLN
DEAL COVERS UP TO FIVE PROGRAMS, TARGETS MONTHLY AND QUARTERLY DOSING FOR OBESITY, DIABETES DRUGS
EUR 615 MLN OF DEAL VALUE COMPRISES UPFRONT, DEVELOPMENT AND REGULATORY MILESTONES
Source text for Workspace: nMFNc51q1r
Further company coverage: NANEXA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Novo Nordisk A/S
See all newsFocus: Beauty giants target 'Ozempic face' as boom in obesity drugs opens new market
Factbox: Anthropic's public benefit fund and how it compares with other big philanthropic efforts
Novo's CagriSema helped women lose 25% of weight on average, analysis shows
As weight-loss drug users turn to dietary supplements, doctors, regulators raise flags
Factbox: Major drugmakers turn to China for licensing deals